[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100549349":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":25,"centralContacts":30,"locations":40,"responsibleParty":53,"collaborators":20,"id":55,"slug":56,"hasResults":57,"nctId":58,"briefTitle":59,"officialTitle":59,"acronym":60,"eligibilityCriteria":61,"healthyVolunteers":62,"sex":63,"minAge":64,"maxAge":20,"enrollmentInfo":65,"targetDuration":20,"studyType":68,"phases":69,"briefSummary":71,"conditions":72,"keywords":74,"overallStatus":79,"whyStopped":20,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":89},{"fullName":5,"class":6},"Institut Pasteur","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Non-febrile adults of Melanesian and European origin","OTHER","Saliva samples and 20 mL blood samples from individuals of Melanesian and European origin from NC",[13,14],"Other: Blood collection","Other: saliva collection",[16,21],{"type":10,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"Blood collection","20 ml-blood sample",[9],null,{"type":10,"name":22,"description":23,"armGroupLabels":24,"otherNames":20},"saliva collection","saliva sample",[9],[26],{"name":27,"affiliation":28,"role":29},"Marc Jouan, MD","Institut Pasteur de Nouvelle-Calédonie","PRINCIPAL_INVESTIGATOR",[31,36],{"name":32,"role":33,"phone":34,"phoneExt":20,"email":35},"Catherine Inizan, PhD","CONTACT","+687 27 26 66","cinizan@pasteur.nc",{"name":37,"role":33,"phone":38,"phoneExt":20,"email":39},"Myrielle Dupont-Rouzeyrol, PhD","+687 27 75 30","mdupont@pasteur.nc",[41],{"facility":28,"status":20,"city":42,"state":20,"zip":43,"country":44,"countryCode":20,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"Noumea","98 835","New Caledonia",{"type":46,"coordinates":47},"Point",[48,49],166.44884,-22.27407,{"lat":49,"lon":48},[52],{"name":27,"role":33,"phone":20,"phoneExt":20,"email":20},{"type":54,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100549349","genetic-determinants-of-the-antiviral-immune-response-in-oceanian-populations-100549349",false,"NCT06432855","Genetic Determinants of the Antiviral Immune Response in Oceanian Populations","GEDIPOP","Inclusion Criteria:\n\n* Adult\n* Non-febrile\n* Self-declared member of the Melanesian or European community\n* Having given consent to participate in the study\n\nExclusion Criteria:\n\n* People who have taken part in a clinical study in the last 6 months in which they were exposed to a health product as part of the investigation (pharmaceutical product or device or placebo).\n* People taking part in an ongoing clinical study\n* People declaring themselves to belong to two communities (e.g. people of mixed European and Melanesian descent)\n* Pregnant and breast-feeding women (in whom the immune response could be modified)\n* People with a long-term medical condition (as defined by the French social security system) that could have an effect on the immune response, excluding dengue risk factors prevalent in New Caledonia such as diabetes, overweight\u002Fobesity and hypertension.\n* Individuals with an acute infection (viral, bacterial or fungal) within 3 months of inclusion.\n* Chronic administration (for more than 14 days) of immunosuppressants or treatments affecting the immune system in the 6 months prior to inclusion. For corticosteroids, this corresponds to a dose equivalent to 20 mg\u002Fday of prednisone or equivalent for more than two weeks (inhaled or topical steroids are permitted).\n* Administration of a vaccine within 3 months prior to inclusion.\n* Administration of blood products or immunoglobulins within 3 months of inclusion.\n* People with known allergies to antibiotics, which could have an impact on the in vitro culture of PBMCs in the presence of antibiotics\n* Persons not intellectually capable of answering the questionnaire\n* Persons under guardianship, curatorship or any other legal incapacity",true,"ALL","18 Years",{"count":66,"type":67},220,"ESTIMATED","INTERVENTIONAL",[70],"NA","Oceania's populations, including Melanesians, are paying a heavy price for dengue fever, which has been circulating actively in the region since the Second World War. In New Caledonia (NC), the incidence of dengue fever is higher among municipalities predominantly populated by Melanesians, suggesting that Melanesians may have an increased susceptibility to symptomatic dengue fever. Differences in antiviral immune responses between populations of different geographical origins are partly the result of population-specific immune regulatory variants. In turn, viruses have imposed considerable selective pressure on human populations. Although crucial to understanding their susceptibility to viral infections, the genetic determinants of the antiviral immune response of Oceanians remain to be characterized.\n\nIn this context, the hypothesis is that the genetic origin of Oceanians, and Melanesians in particular, has shaped their antiviral immune response and contributes to their greater susceptibility to certain viral infections. The aim is to characterize the immune response to pathogens affecting the New Caledonian population, and in particular to dengue virus, of Melanesian and European populations, and to identify its genetic determinants. It will be explored whether saliva can be used as a non-invasive sample to study the seroprevalence of dengue in Oceanian populations.",[73],"Virus",[75,76,77,78,44],"dengue","immunity","genetics","Ocenian populations","NOT_YET_RECRUITING","2024-06-20",{"date":82,"type":83},"2024-06-24","ACTUAL",{"date":85,"type":67},"2024-06-15",{"date":87,"type":67},"2027-12-15",{"name":5,"class":6},1]